HDT BIO
We are a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. In 2014, the U.S. market for immune therapeutics was estimated at $1.4 billion and it is projected to grow to $27 billion by 2021. Assets in our portfolio include activators of innate and adaptive immune responses. A distinguishing factor to these is the formulation expertise which enables these technologies by targeting them to local and systemic sites in the body where they ar... e needed. Since they affect the host and not the pathogen it will be difficult for resistance to emerge. Thus, we see an opportunity to apply the latest technologies in immunology to expand the benefits of immunotherapy to all. Our founders are world leaders in the development of adjuvants and immune therapeutics and have developed a number of these immune stimulants in the past in their work with multiple successful spin-out exits. They are joined by experienced entrepreneurs with expertise in biotechnology operations, finance, intellectual property, legal and strategy.
HDT BIO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.hdt.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
18.95 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Similar Organizations
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
US Army
US Army investment in Grant - HDT Bio
National Institutes of Health
National Institutes of Health investment in Grant - HDT Bio
Eric Anschutz
Eric Anschutz investment in Seed Round - HDT Bio
Zoic Capital
Zoic Capital investment in Seed Round - HDT Bio
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - HDT Bio
Official Site Inspections
http://www.hdt.bio Semrush global rank: 3.11 M Semrush visits lastest month: 5.17 K
- Host name: gra.graphicainc.com
- IP address: 162.241.142.33
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "HDT Bio"
About Us - HDT Bio
HDT Bio is dedicated to combining for-profit goals with global health equity objectives. The company’s strategy emphasizes an integrative approach, generating platform and product …See details»
Our Team - HDT Bio
HDT Bio has created an ecosystem of leadership and expertise that will accelerate its products towards clinical valuation and global access. Careers at HDT Bio. We are proud of our …See details»
HDT Bio - Crunchbase Company Profile & Funding
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, …See details»
HDT Bio Company Profile 2024: Valuation, Funding
HDT Bio has raised $14.5M. Who are HDT Bio’s investors? National Institute for Allergy and Infectious Disease, Eric Anschutz, Mathew Spolin, Zoic Capital , and U.S. Department of Health and Human Services have invested in HDT Bio.See details»
HDT Bio Corp. - Drug pipelines, Patents, Clinical trials - Synapse
Explore HDT Bio Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 18 news, and 17 literature, Disease Domain:Infectious Diseases, Neoplasms, Endocrinology …See details»
HDT Bio - LinkedIn
HDT Bio | 5,582 followers on LinkedIn. Immune Therapy For All | HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases ...See details»
HDT Bio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - HDT Bio . Eric …See details»
HDT Bio - Contacts, Employees, Board Members, Advisors & Alumni
HDT Bio has 6 current employee profiles, including Chief Technology Officer Peter Berglund. Peter Berglund Chief Technology Officer Steven Reed Co-Founder & CEOSee details»
HDT Bio Company Profile - Office Locations, Competitors ... - Craft
HDT Bio is a biopharmaceutical company intended to develop biotherapeutics for oncology and infectious disease applications. Its immunotherapy enhances the patient's own immune …See details»
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
Aug 14, 2023 In focus with: Steve Reed, CEO, co-founder, HDT Bio HDT Bio’s vision: mRNA has already proved its worth in the fight against infectious diseases.Now Seattle-based HDT …See details»
Partnerships - HDT Bio
HDT Bio and the University of Texas Medical Branch were awarded a project agreement worth $87.4 million and up to $250 million in milestones to utilize its repRNA/LION™ platform to …See details»
HDT-201 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated …See details»
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 …
Aug 31, 2021 HDT Bio is actively commercializing its COVID-19 RNA vaccine technology in ... It also reported that India’s Central Drugs Standard Control Organization has approved initiation …See details»
HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of
Mar 29, 2022 SEATTLE--(BUSINESS WIRE)-- HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, today announced the first healthy volunteer has been …See details»
Technology - HDT Bio
With LION™, HDT Bio is committed to advancing global health by fighting infectious diseases and improving access to preventative healthcare for all. Cost-Effective Global Distribution This …See details»
HDT Bio Awarded $2.9M NIH Grant to Develop RNA Vaccine for …
May 17, 2021 HDT Bio’s HIV vaccine research will use the same self-replicating RNA technology employed with its COVID-19 RNA vaccine, HDT-301, which is in clinical trials in India in …See details»
HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next ...
Mar 29, 2022 To support HDT Bio’s mission of reducing global heath inequities, the company has RNA vaccine collaborations underway with partners in China, Korea, and Brazil for its …See details»
HDT Bio To Make Corporate Presentation at BioFuture Investor …
SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate …See details»
Pipeline - HDT Bio
Infectious Diseases. HDT Bio’s COVID-19 vaccine, HDT-301, is in Phase 1 clinical trial in the US. Other COVID-19 vaccines developed using HDT Bio’s AMPLIFY platform have been …See details»